Journey Medical Price To Earning vs. Net Income
| DERM Stock | USD 6.63 -0.32 -4.60% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.74 | 0.72 |
|
|
This view for Journey Medical Corp frames profitability through return on assets, equity, and margin metrics. All ratios are based on standardized financial reporting inputs. Return metrics highlight how efficiently the company generates earnings from its resource base. Profitability data is presented without directional implication.
Revenue Breakdown by Segment
Journey Medical generates revenue across 2 reported product segments. At 7.36 Million, Qbrexza is Journey Medical's largest segment (72.7%), with Accutane as the second-largest at 2.77 Million. With the top segment exceeding 60% of revenue, Journey Medical's earnings are heavily concentrated in a single product line.
Investing Opportunities.
Macro event markers
Earnings Segment Revenue Breakdown for Journey Medical Details
The breakdown below shows how Journey Medical's revenue is split across product segments for the most recent reporting period. The smallest reported segment is Accutane at 27.3% of total revenue.
Consensus earnings data provides a reference point for evaluating Journey Medical over time. These figures serve as informational inputs within a broader research framework. The information is grounded in publicly filed financial statements and disclosures.
Earnings Share -0.35 | Revenue Per Share | Quarterly Revenue Growth 0.205 | Return On Assets | Return On Equity |
Comparing Journey Medical's market price with book value reveals how market sentiment relates to accounting fundamentals. Journey Medical's market capitalization is 231.13 M. The 8.91 P/B ratio shows Journey Medical carries a substantial premium over its balance-sheet equity. Enterprise value stands at 231.15 M. Intrinsic value represents an estimate of underlying worth and can differ from both market price and book value. Analytical frameworks help reconcile those views into a coherent picture.
The concept of value for Journey Medical differs from its quoted price, since each reflects a different lens. For Journey Medical, key inputs include a P/B ratio of 8.91, a profit margin of -14.58%, ROE of -47.05%, and revenue of 56.13 M. Where Journey Medical trades at any moment depends on the balance of buying and selling pressure.
Journey Medical Corp Net Income vs. Price To Earning Fundamental Analysis
Comparative valuation applies peer-based financial ratios to assess Journey Medical's relative market value. Journey Medical Corp lands at #4 in price to earning compared to key competitors. It also lands at #4 in net income compared to key competitors . Forward estimates place Net Loss near -17.72 Million, implying a recovering bias. Year-ago financials show Journey Medical with Net Loss of -16.87 Million. Relative ratio analysis evaluates Journey Medical's earnings valuation.Journey Net Income vs. Price To Earning
Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Journey Medical |
| = | -9.50 X |
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Journey Medical |
| = | -14.67 M |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Journey Net Income Comparison
Journey Medical is currently under evaluation in net income compared to key competitors.
Journey Medical Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Journey Medical, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Journey Medical will eventually generate negative long term returns. The profitability progress is the general direction of Journey Medical's change in net profit over the period of time. It can combine multiple indicators of Journey Medical, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | End Of Year Estimate | ||
| Operating Income | -15.7 M | -16.5 M | |
| Income Before Tax | -16.8 M | -17.6 M | |
| Total Other Income Expense Net | -840.6 K | -882.6 K | |
| Net Loss | -16.9 M | -17.7 M | |
| Income Tax Expense | 54.9 K | 52.2 K | |
| Net Interest Income | -1.7 M | -1.8 M | |
| Net Loss | -13.2 M | -13.9 M | |
| Net Loss | -26.7 M | -25.3 M | |
| Interest Income | 870.5 K | 914.1 K | |
| Change To Netincome | 25.3 M | 26.5 M | |
| Net Loss | -0.65 | -0.68 | |
| Income Quality | 0.72 | 0.69 | |
| Net Income Per E B T | 0.90 | 0.76 |
Journey Profitability Driver Comparison
Understanding Journey Medical's profitability drivers is a critical part of evaluating Journey Medical as an investment. Unexpected events - from regulatory changes to commodity price movements - can materially alter the profit trajectory and investment outlook during any given holding period.
Earnings Estimation Breakdown
Based on trailing twelve-month earnings reporting, analysts project Journey Medical's next EPS at 0.063125. The range of analyst estimates extends from 0.0425 on the low end to 0.09 on the high end for Journey Medical Corp. Non-recurring items are excluded from this projection to ensure that the estimate reflects sustainable earnings capacity.Last Reported EPS
0.04 Lowest | Expected EPS | 0.09 Highest |
Earnings Projection Consensus
A consensus EPS-based fair value estimate above Journey Medical's current market price may suggest the stock is trading below intrinsic value by some metrics. An estimate below market price raises questions about whether the current valuation is sustainable without stronger earnings growth. Both interpretations are scenario-based and should be paired with fundamental due diligence and risk assessment before allocation.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2026 | Current EPS (TTM) | |
| 4 | 55.39% | 0.0 | 0.063125 | -0.35 |
Earnings History
Professional analysts covering Journey Medical revise EPS estimates throughout the quarter based on new data, guidance updates, and sector shifts. The final consensus ahead of the earnings date becomes the reference point against which reported results are judged. Comparing consensus trends to actual outcomes over multiple quarters reveals analytical reliability over time.Journey Medical Quarterly Gross Profit | 11.88 Million |
Experienced Journey Medical's investors use mean reversion as a complement to momentum analysis: momentum identifies the trend; mean reversion identifies when that trend has extended beyond sustainable levels.
Earnings per Share Projection vs Actual
The distinction between actual and expected EPS for Journey Medical is foundational to earnings analysis. Actual EPS is confirmed at the close of each reporting cycle; expected EPS is the analyst consensus formed before reporting. Higher EPS is generally associated with stronger profitability, and the weighted average methodology ensures fairness when share counts fluctuate.Estimated Months Earnings per Share
Income-focused investors in Journey Medical use EPS trends as a proxy for dividend sustainability and future payout growth. Rising EPS supports the ability to maintain or increase distributions; declining EPS may signal payout risk. For best results, EPS should be evaluated alongside payout ratio, free cash flow, and peer comparisons.Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises represent the gap between what Journey Medical reports and what the analyst community projected - a gap that markets price rapidly and often decisively. Both the direction and magnitude of the surprise influence the near-term trend after results are published. Analyst EPS estimates are built from guidance, sector trends, and detailed financial models updated throughout the quarter.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
null | null | null | null | null | 0 | ||
2025-11-12 | 2025-09-30 | -0.03 | -0.09 | -0.06 | 200 | ||
2025-08-12 | 2025-06-30 | -0.11 | -0.16 | -0.05 | 45 | ||
2025-06-25 | 2025-03-31 | -0.2375 | -0.18 | 0.0575 | 24 | ||
2025-03-26 | 2024-12-31 | -0.1725 | 0.1 | 0.2725 | 157 | ||
2024-11-12 | 2024-09-30 | -0.17 | -0.12 | 0.05 | 29 | ||
2024-08-06 | 2024-06-30 | -0.15 | -0.17 | -0.02 | 13 | ||
2024-05-13 | 2024-03-31 | -0.23 | -0.53 | -0.3 | 130 | ||
2024-03-21 | 2023-12-31 | -0.08 | -0.12 | -0.04 | 50 | ||
2023-11-07 | 2023-09-30 | -0.15 | 0.8 | 0.95 | 633 | ||
2023-08-08 | 2023-06-30 | -0.33 | -0.29 | 0.04 | 12 | ||
2023-05-22 | 2023-03-31 | -0.45 | -0.57 | -0.12 | 26 | ||
2023-03-29 | 2022-12-31 | -0.47 | -0.6 | -0.13 | 27 | ||
2022-11-10 | 2022-09-30 | -0.4 | -0.57 | -0.17 | 42 | ||
2022-08-09 | 2022-06-30 | -0.26 | -0.43 | -0.17 | 65 | ||
2022-05-10 | 2022-03-31 | -0.31 | -0.08 | 0.23 | 74 | ||
2022-03-23 | 2021-12-31 | -0.41 | -1.64 | -1.23 | 300 | ||
2021-12-10 | 2021-09-30 | -0.87 | 0.32 | 1.19 | 136 | ||
2021-09-01 | 2021-06-30 | -1.3 | -0.72 | 0.58 | 44 | ||
2019-11-05 | 2019-09-30 | -1.3 | -1.06 | 0.24 | 18 | ||
2019-08-07 | 2019-06-30 | -0.95 | -0.33 | 0.62 | 65 | ||
2019-05-07 | 2019-03-31 | -1.62 | -1.49 | 0.13 | 8 | ||
2019-02-26 | 2018-12-31 | -1.91 | -1.7 | 0.21 | 10 | ||
2018-11-07 | 2018-09-30 | -1.63 | -1.58 | 0.05 | 3 | ||
2018-08-06 | 2018-06-30 | -0.51 | -0.57 | -0.06 | 11 | ||
2018-05-03 | 2018-03-31 | -1.36 | -1.42 | -0.06 | 4 | ||
2018-02-22 | 2017-12-31 | -1.22 | -1.34 | -0.12 | 9 | ||
2017-11-06 | 2017-09-30 | -1.12 | -4.3 | -3.18 | 283 | ||
2017-08-07 | 2017-06-30 | -0.89 | -0.93 | -0.04 | 4 | ||
2017-05-08 | 2017-03-31 | -0.89 | -0.79 | 0.1 | 11 | ||
2017-02-28 | 2016-12-31 | -0.8 | -0.21 | 0.59 | 73 | ||
2016-11-07 | 2016-09-30 | -0.72 | -0.72 | 0.0 | 0 | ||
2016-08-08 | 2016-06-30 | -0.86 | -0.89 | -0.03 | 3 | ||
2016-05-10 | 2016-03-31 | -0.94 | -0.95 | -0.01 | 1 | ||
2016-03-03 | 2015-12-31 | -0.95 | -1.04 | -0.09 | 9 | ||
2015-11-10 | 2015-09-30 | -0.77 | -0.58 | 0.19 | 24 | ||
2015-08-13 | 2015-06-30 | -0.75 | -0.69 | 0.06 | 8 | ||
2015-05-12 | 2015-03-31 | -0.65 | -0.57 | 0.08 | 12 | ||
2015-03-25 | 2014-12-31 | -0.6 | -0.29 | 0.31 | 51 | ||
2014-11-12 | 2014-09-30 | -0.93 | -8.67 | -7.74 | 832 |
Use Journey Medical in pair-trading
Pair analysis around Journey Medical Corp matters because it can turn one security idea into a more market-neutral structure. The advantage is that adverse movement in one leg may be partly offset by the other when correlation and thesis alignment hold.
Journey Medical Pair Trading
Journey Medical Corp Pair Trading Analysis
Identifying correlated replacements for Journey Medical is particularly important in concentrated portfolios where Journey Medical Corp represents a large allocation. A poor substitute could introduce unintended factor or sector risks that persist beyond the required waiting period.
Correlation is not causation, but for Journey Medical it is a practical tool. High correlations between Journey Medical Corp and a potential addition to the portfolio flag concentrated exposure, while low correlations signal diversification potential.
Pair trading evaluation alongside Correlation analysis adds hedging context for Journey Medical. The hedging framework is applicable across related stocks and broader market groups.Use Investing Themes to Complement your Journey Medical position
At 231.13 Million in the Drug Manufacturers—Specialty & Generic space, Journey Medical Corp smaller-cap profile gives investors a structured starting point for building sector-aligned themes. For Journey Medical Corp in Drug Manufacturers—Specialty & Generic, the theme workflow defines the investment thesis first, then optimizes which Healthcare assets best express that view at the smaller-cap level.
Did You Try This Idea?
Run Obamacare Repeal Thematic Idea Now
Obamacare Repeal
Healthcare and drug manufacturing companies that will most likely be affected by the final stages of Obamacare repeal. The Obamacare Repeal theme has 56 constituents at this time.
Investors can hold the Obamacare Repeal Theme as a long-term basket or actively trade individual constituents to capture short-term price movement.
| View All Next | Launch |